Evidence map›Paper›PMID 34124345›Full record

ArticleTransplantation direct2021

Renal Protective Effect of Everolimus in Liver Transplantation: A Prospective Randomized Open-Label Trial.

Zakiyah Kadry, Jonathan G Stine, Takehiko Dohi, Ashokkumar Jain, Kimberly L Robyak, Osun Kwon, Christopher J Hamilton, Piotr Janicki, Thomas R Riley, Fauzia Butt and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Basics and Art of Immunosuppression in Liver Transplantation.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Zakiyah KadryDivision of Transplantation, Department of Surgery, Penn State College of Medicine, Hershey, PA.
Jonathan G StineDivision of Gastroenterology and Hepatology, Department of Medicine, Penn State College of Medicine, Hershey, PA.
Takehiko DohiDivision of Transplantation, Department of Surgery, Penn State College of Medicine, Hershey, PA.
Ashokkumar JainDivision of Transplantation, Department of Surgery, Penn State College of Medicine, Hershey, PA.
Kimberly L RobyakDepartment of Pathology, Penn State College of Medicine, Hershey, PA.
Osun KwonDivision of Nephrology, Department of Medicine, Penn State College of Medicine, Hershey, PA.
Christopher J HamiltonDepartment of Pathology, Penn State College of Medicine, Hershey, PA.
Piotr JanickiDepartment of Anesthesiology, Penn State College of Medicine, Hershey, PA.
Thomas R RileyDivision of Gastroenterology and Hepatology, Department of Medicine, Penn State College of Medicine, Hershey, PA.
Fauzia ButtDivision of Transplantation, Department of Surgery, Penn State College of Medicine, Hershey, PA.
Karen KrokDivision of Gastroenterology and Hepatology, Department of Medicine, Penn State College of Medicine, Hershey, PA.
Ian R SchreibmanDivision of Gastroenterology and Hepatology, Department of Medicine, Penn State College of Medicine, Hershey, PA.
Dmitri BezinoverDepartment of Anesthesiology, Penn State College of Medicine, Hershey, PA.
Nasrollah GhahramaniDivision of Nephrology, Department of Medicine, Penn State College of Medicine, Hershey, PA.
Stalin CamposDivision of Transplantation, Department of Surgery, Penn State College of Medicine, Hershey, PA.
Christopher S HollenbeakDepartment of Health Policy and Administration, Pennsylvania State University, University Park, PA.
Penn State Milton S. Hershey Medical Center · USPennsylvania State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal dysfunction is associated with poor long-term outcomes after liver transplantation. We examined the renal sparing effect of everolimus (EVR) compared to standard calcineurin inhibitor (CNI) immunosuppression with direct measurements of renal function over 24 months.

methodsThis was a prospective, randomized, open-label trial comparing EVR and mycophenolic acid (MPA) with CNI and MPA immunosuppression. An Investigational New Drug Application (IND # 113882) was obtained with the Food and Drug Administration as EVR is only approved for use with low-dose tacrolimus. Serum creatinine, 24-hour urine creatinine clearance, iothalamate clearance, Cockcroft-Gault creatinine clearance (CrCl), and Modification of Diet in Renal Disease estimated glomerular filtration rate were prospectively measured at 4 study visits. Nonparametric statistical tests were used for analyses, including the Mann-Whitney U test for continuous outcomes and Pearson's chi-square test for binary outcomes. Effect size was measured using Cohen's

resultsEach arm had 12 subjects; 4 patients dropped out in the EVR arm and 1 in the CNI arm by 24 months. Serum creatinine (

conclusionsEVR with MPA resulted in significant long-term improvement in renal function and quality of life at 24 months after liver transplantation compared with standard CNI with MPA immunosuppression.

Identifiers

PMID34124345
PMCPMC8191692
OpenAlexW3169014724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.